Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Vincent Buchheit"'
Autor:
Georgina Meneses-Lorente, Elena Guerini, Francois Mercier, Neil Parrott, Karey Kowalski, Edna Chow-Maneval, Vincent Buchheit, Guillaume Bergthold, Elizabeth Fox, Alex Phipps, Nassim Djebli
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:239-246
Purpose Entrectinib is a central nervous system-active potent inhibitor of tropomyosin receptor kinase (TRK), with anti-tumor activity against neurotrophic NTRK gene fusion-positive tumors. This study investigates the pharmacokinetics of entrectinib
Autor:
Nassim Djebli, Pierre-Olivier Tremblay, Vincent Buchheit, Mario González-Sales, Guillaume Bonnefois, Georgina Meneses-Lorente, Francois Mercier, Nicolas Frey
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:997-1007
Entrectinib (ROZLYTREK®) is a CNS-active, potent, and selective inhibitor of ROS1, TRK A/B/C, and ALK kinase activity. It was recently approved for the treatment of ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors.
Autor:
Li Yu, Elena Guerini, Georgina Meneses-Lorente, Alex Phipps, Vincent Buchheit, Nassim Djebli, Francois Mercier, Yumi Cleary, Stephen Fowler, Nicolas Frey, Neil Parrott
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 46:779-791
Entrectinib is a selective inhibitor of ROS1/TRK/ALK kinases, recently approved for oncology indications. Entrectinib is predominantly cleared by cytochrome P450 (CYP) 3A4, and modulation of CYP3A enzyme activity profoundly alters the pharmacokinetic
Autor:
Darren Bentley, Nassim Djebli, Andreas Brink, Edna Chow-Maneval, Elena Guerini, Karey Kowalski, Vincent Buchheit, Francois Mercier, Georgina Meneses-Lorente, Alex Phipps, Li Yu
Publikováno v:
Investigational New Drugs
SummaryBackground: Entrectinib is an oral, CNS-active, potent inhibitor of tyrosine receptor kinases A/B/C, tyrosine kinase ROS proto-oncogene 1, and anaplastic lymphoma kinase approved for use in patients with solid tumors. We describe 3 clinical st
Autor:
Günter Fingerle-Rowson, Ekaterina Gibiansky, Michael Brewster, Vincent Buchheit, Candice Jamois, Nicolas Frey, Leonid Gibiansky
Publikováno v:
British Journal of Clinical Pharmacology
Aims Rituximab is standard care in a number of lymphoma subtypes, including follicular lymphoma (FL), although many patients are resistant to rituximab, or develop resistance with repeated treatment, and a high proportion relapse. Obinutuzumab is a n
Autor:
Dietmar Schwab, Norman A. Mazer, Valerie Cosson, Cheikh Diack, Nicolas Frey, Vincent Buchheit
Publikováno v:
Translational Vision Science & Technology
Purpose What are the patient characteristics predictive of response to ranibizumab treatment? Methods Model-based characterization of best-corrected visual acuity (BCVA) time profiles of patients with neovascular age-related macular degeneration unde
Autor:
D J Carlile, Vincent Buchheit, Nicolas Frey, Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Treatment regimens involving obinutuzumab (GA101) demonstrated increased efficacy to rituximab in clinical trials for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). However, the pharmacokinetic (PK) properties and the exposure
Autor:
Vincent Buchheit, Angelika Lahr, Francois Mercier, Christophe Boetsch, Benjamin Ribba, Alex Phipps, Kevin Smart, Oliver Krieter
Publikováno v:
Journal of Clinical Oncology. 34:e17042-e17042
e17042Background: Vanucizumab is a novel bi-specific IgG-like antibody which is directed against both VEGF-A and ANG2, two key factors in tumor angiogenesis. As such, vanucizumab represents an enco...
Autor:
Ekaterina Gibiansky, Wolfgang Hiddemann, Robert Marcus, John F. Seymour, Georgina Meneses-Lorente, Guillaume Cartron, Nicolas Frey, Denis Sahin, Chantal E. Hargreaves, Günter Fingerle-Rowson, Candice Jamois, Vincent Buchheit, Leonid Gibiansky, Jonathan C. Strefford
Publikováno v:
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, Wiley, 1970, 85 (7), pp.1495-1506. ⟨10.1111/bcp.13920⟩
British Journal of Clinical Pharmacology, Wiley, 1970, 85 (7), pp.1495-1506. ⟨10.1111/bcp.13920⟩
Aims: Obinutuzumab (G) is a humanized type II, Fc-glycoengineered anti-CD20 monoclonal antibody used in various indications, including patients with previously untreated front-line follicular lymphoma. We investigated sources of variability in G expo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2923de3729f8a8856af7d63db540b0c
https://hal.umontpellier.fr/hal-02879699
https://hal.umontpellier.fr/hal-02879699